When Jennifer Doudna and Emmanuelle Charpentier revealed that the bacterial Crispr–Cas9 antiviral defence system could be reprogrammed to edit genomic DNA they could scarcely have imagined the impact their discovery would have. One Nobel prize and a decade later treatments based on the technique are racing towards the clinic. Read more in Chemistry World.